

Study commenced and recruitment initiated at Joondalup Health Campus

- **HeraBEAT clinical study underway at Joondalup Health Campus remains on track**
- **The study is registered on the Australian and New Zealand Clinical Trial Register ACTRN12620000739910**
- **Recruitment of participants has commenced and progresses well according to expectations**

HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care with its proprietary in-home pregnancy monitoring platform, is pleased to announce that the clinical study at the Joondalup Health Campus in Western Australia (the “Study”), is on track and provides the following progress report.

In an important step, the Study has now been registered on the Australian and New Zealand Clinical Trial Register (ANZCTR) and can be found [here](#). The recruitment of participants has now commenced.

The Study is recruiting 60 expectant mothers over the age of 18 years with a singleton pregnancy from 12 weeks gestation and is attending the Joondalup Health Campus antenatal clinic.

This represents an important step forward for the Study and HMD as it enables the researchers to collect and analyse the data including accuracy, user-friendliness, and user’s satisfaction, providing further clinical validation for its solutions and setting a new standard of care in remote, foetal and maternal wellbeing.

Next Steps

- **Step 1**, which has already commenced, includes the recruitment of participants and assessment by clinical staff (JHC antenatal clinic), evaluating accuracy levels by a professional comparing the HeraBEAT to a hospital CTG machine.
- **Step 2**, includes use and assessment by the expectant mother, evaluating usability, ease of use and user satisfaction at the clinic and measured by the international medical standard System Usability Scale (SUS).
- **Step 3** highlights and evaluates remote home monitoring; using the HeraBEAT device for recording continuous FHR trace by the mother, electronically transmitted to the obstetrician/midwife for review and consultations. An assessment of the transmission, including data clarity and clinical utility, will be made by the antenatal team

It is estimated that the study will complete within 2 months.

CEO and Co-founder Mr David Groberman said: “Working with the highly experienced team at Joondalup Health Campus demonstrates how effective our technology is and commencing recruitment is an important step forward. We are optimistic about the progress and believe the positive results will have a significant impact on the company’s progress both clinically as well as commercially. Once the study accomplishes its main objectives, we will have the required scientific and clinical data supporting our technology’s accuracy, usability, efficiency and acceptability by both clinical staff as well as expecting mothers; It will ideally position HeraMED to expedite our rollout to the Australian and international markets validating our digital, connected pregnancy care platform allowing expectant mothers to use the devices at home to obtain accurate monitoring; and this will allow the safe transition to a reduction in face-to-face antenatal visits whilst enhancing the overall prenatal experience for pregnant women”

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: David@hera-med.com

Company Secretary

Jonathan Hart

T: +61 2 8379 2961

E: Jonathan@hera-med.com

Media Enquiries

Melissa Hamilton

Media & Capital Partners

M: +61 4 1775 0274

E: Melissa.hamilton@mcpartners.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical technology company leading the digital transformation of maternity care by revolutionising the pregnancy experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital dashboard.

About HeraCARE

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.